Abstract
Sixty-four patients with non metastatic high risk breast cancer were randomized in a double blind trial of adjuvant immunotherapy with sodium ditiocarb (DDC) versus placebo. All patients underwent prior surgery (mammectomy according to Patey) then adjuvant FAC chemotherapy +/- DDC. With a median follow-up of 5 years we observed 6 relapses and 5 deaths in DDC group; 13 relapses and 12 deaths in control group. At 6 years, overall survival is 81% in DDC group versus 55%. Disease free survival (DFS) is 76% in DDC group versus 55%. DDC associated to chemotherapy and locoregional treatment can improve survival and probably DFS in this high risk breast cancer subgroup.
Similar content being viewed by others
Abbreviations
- DDC:
-
sodium ditiocarb
- DFS:
-
disease free survival
- OS:
-
overall survival
- N:
-
node
- FAC:
-
5 Fluorouracil, Adrianycin, Cyclopho-pharmide
References
Early breast cancer trialists' collaborative group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992; 339: 71–85.
Mathe G, Amiel J-L, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, de Vassal F. Active immunotherapy for acute lymphoblastic leukemia. Lancet 1969; 1; 697.
Smith GV, Morese PA, Deraps GD, Raju S, Hardy JD Immunotherapy of patients with cancer. Surgery 1973; 74: 59–68.
Renoux G, Renoux M Thymus-like activities of sulphur derivatives on T-cell differentiation. J Exp Med, 1977, 145, 466–471.
Perchellet J-P, Abney NL, Thomas RM, Perchellet EM, Maatta EA: Inhibition of multistage tumor promotion in mouse skin by-diethyldithiocarbamate. Cancer Res, 1987, 6302–6309.
Kumar KS, Sancho AM, Weiss JF: A novel interaction of diethyldithiocarbamate with the glutathione/glutathione peroxydase system. Int J Rad Oncol, 1986, 12, 1463–1467.
Rojas AF, Mickiewicz E, Feierstein JN, Glait H, Olivari AJ: Levamisole in advanced human breast cancer. Lancet, 1976, 1, 212–215.
Klefström P, Nuortio L. Levamisole in the treatment of advanced breast cancer. Act Oncol, 1991, 30, 347–352.
Treurniet-Donker AD, Meischke-de Jong ML, van Putten WLJ: Levamisole as adjuvant immunotherapy in breast cancer. Cancer, 1987, 59, 1590–1593.
Betzler M, Schreml W, Lang M, Lohrmann HP, Flad HD, Schlag P, Herfarth C, Hiempel H: Adjuvant intermittent chemoimmunotherapy for primary breast cancer: a prospective study with immunologic follow-up. Recent Results Cancer Res, 1982, 80, 185–191.
Executive Committee of the Danish Breast Cancer Cooperative Group: Increased breast-cancer recurrence rate after adjuvant therapy with levamisole. Lancet, 1980, 2, 824–827.
Giuliano AE, Sparks FC, Patterson K, Spears I, Morton DL: Adjuvant chemo-immunotherapy in stage II carcinoma of the breast. J Surg Oncol, 1986, 31, 255–259.
Hubay CA, Pearson OH, Manni A, Gordon NH, McGuire WL: Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6-year result. J Steroid Biochem, 1985, 23, 1147–1150.
Gutterman JU, Cardenas JO, Blumenschein GR, Hortobagyi G, Burgess MA, Livingston RB, Mavligit GM, Freireich EJ, Gottlieb JA, Hersch EM: Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. Brit Med J, 1976, 2, 1222–1225.
Lacour J, Lacour F, Ducot B, Spirer A, Michelson M, Petit JY, Sarrazin D, Contesso G: Polyadenylic-polyuridilic acid as adjuvant in the treatment of operable breast cancer: recent results. Eur J Surg Oncol, 1988, 14, 311–316.
Lang J-M, Touraine J-L, Trepo C & AIDS-Imuthiol french study group: Randomised, double-blind, placebo-controlled trial of ditiocarbsodium (“Imuthiol”) in human immunodeficiency virus infection. Lancet, 1988, 2, 702–705.
Hersh EM, Brewton G, Aabrams D, Bartlett J, Galpin J, Gill P, Gorter R, Gottlieb M, Jonikas JJ, Landesman S, Levine A, Marcel A, Petersen EA, Whitside M, Zahradnik J, Negron C, Boutitie F, Caraux J, Dupuy J-M, Salmi LR: Ditiocarb sodium therapy in patients with symptomatic HIV infection and AIDS. JAMA, 1991, 265, 1538–1544.
Lin PS, Kwock L, Goodchild NT. Copper chelator enhancement of bleomycin cytotoxicity. Cancer, 1980, 48, 2360–2364.
Borch RF, Pleasants ME Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model. Proc Natl Acad Sci, 1979, 76, 6611–6614.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dufour, P., Lang, J.M., Giron, C. et al. Sodium ditiocarb as adjuvant immunotherapy for high risk breast cancer: A randomized study. Biotherapy 6, 9–12 (1993). https://doi.org/10.1007/BF01877380
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01877380